샘플 요청 목록

 카트 문의
시장보고서
상품코드
1785719

세계의 강직성 척추염 시장

Ankylosing Spondylitis
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 271 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 강직성 척추염 시장은 2030년까지 81억 달러에 이를 전망

2024년에 60억 달러로 추정되는 강직성 척추염 세계 시장은 2024-2030년의 분석 기간에 CAGR 5.2%로 성장하여 2030년에는 81억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 TNF 억제제 약제 클래스별은 CAGR6.1%를 나타내고, 분석 기간 종료시에는 44억 달러에 이를 것으로 예측됩니다. NSAIDs 약제 클래스별 성장률은 분석 기간중 CAGR 4.7%로 추정됩니다.

미국 시장은 16억 달러로 추정, 중국은 CAGR 8.4%로 성장 예측

미국의 강직성 척추염 시장은 2024년에 16억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 16억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 8.4%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 2.5%와 5.3%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 3.4%를 보일 전망입니다.

세계의 강직성 척추염 시장 - 주요 동향과 촉진요인 정리

강직성 척추염이 전 세계적으로 심각한 건강 문제가 되고 있는 이유는 무엇일까?

주로 척추와 천장관절에 영향을 미치는 만성 염증성 질환인 강직성 척추염(AS)은 그 쇠약하게 만드는 특성과 삶의 질에 미치는 장기적인 영향 때문에 전 세계적으로 심각한 건강 문제로 인식되고 있습니다. AS는 주로 젊은 성인에게 발병하며, 10대 후반에서 20대 초반에 증상이 시작되는 경우가 많습니다. 만성 통증, 경직, 잠재적인 척추 고정이 특징인 이 질환의 진행성 특성은 증상을 관리하고 합병증을 예방하기 위한 효과적인 치료 개입의 필요성을 강조합니다. 또한, 전 세계적으로 강직성 척추염의 유병률이 증가함에 따라, 표적화된 치료 옵션에 대한 수요가 증가하고 있습니다. AS의 정확한 원인은 아직 밝혀지지 않았지만, 유전적 소인, 특히 HLA-B27 유전자의 존재가 주요 위험인자로 확인되고 있습니다. 이는 AS 환자를 위한 맞춤형 치료 전략을 가능하게 하는 정밀의료 접근법의 발전을 촉진하고 있습니다. 또한, 생산성 저하, 의료비 증가 등 이 질환의 사회적, 경제적 부담이 크기 때문에 효과적인 치료법에 대한 접근성을 개선하는 것에 대한 관심이 높아지고 있습니다.

AS 치료제 개발의 원동력이 되고 있는 발전은 무엇인가?

강직성 척추염의 치료 상황은 생물학적 제제 및 표적 합성 질환 변형 항류마티스제제(DMARDs)의 발전에 힘입어 크게 발전해 왔습니다. 아달리무맙과 인플릭시맙과 같은 종양괴사인자(TNF) 억제제는 염증을 억제하고 질병의 진행을 지연시키며 환자의 예후를 개선함으로써 AS 치료에 큰 변화를 가져왔습니다. 세쿠키누맙과 익세키주맙을 포함한 인터루킨(IL)-17 억제제의 도입은 특히 TNF 억제제에 반응하지 않는 환자들에게 치료 선택의 폭을 넓혀주고 있습니다. 자가 피하주사, 서방형 제제 등 약물 전달 시스템의 혁신은 환자의 순응도와 편의성을 향상시켰습니다. 또한, 자기공명영상(MRI), 유전자 검사 등 진단 도구의 발전으로 AS의 조기 발견이 용이해져 적시에 개입하고 질병을 더 잘 관리할 수 있게 되었습니다. 야누스 키나아제(JAK) 억제제와 같은 새로운 치료 표적에 대한 지속적인 연구는 가까운 미래에 효과적인 치료 옵션의 폭을 넓힐 수 있는 잠재력을 가지고 있습니다.

지역 역학은 시장 성장에 어떤 영향을 미치고 있는가?

강직성척추염 시장은 질병 유병률, 의료 인프라, 첨단 치료 접근성 등의 차이로 인해 지역별로 큰 차이를 보이고 있습니다. 북미는 높은 자가면역질환 유병률, 탄탄한 헬스케어 시스템, 연구개발에 대한 막대한 투자로 시장을 독점하고 있습니다. 이 지역은 또한 유리한 상환 정책과 첨단 생물학적 제제 보급의 혜택을 누리고 있습니다. 유럽은 조기 진단과 혁신적 치료법을 표준 치료 프로토콜에 통합하는 데 중점을 두고 있으며, 이를 따르고 있습니다. 독일, 영국, 프랑스 등의 국가에서는 류마티스내과 네트워크가 잘 구축되어 있어 더 나은 질병 관리와 환자 결과를 보장하고 있습니다. 아시아태평양에서는 질병에 대한 인식 증가, 의료 서비스 접근성 향상, 가처분 소득 증가로 인해 시장이 빠르게 성장하고 있습니다. 중국, 인도 등 신흥국에서는 의료 인프라를 강화하는 정부 이니셔티브에 힘입어 생물학적 제제의 채택이 확대되고 있습니다. 한편, 라틴아메리카와 중동에서는 가격이나 인지도에 대한 과제가 남아있지만, 첨단 치료법이 점차 받아들여지고 있습니다.

강직성 척추염 시장의 성장 원동력은 무엇인가?

강직성 척추염 시장의 성장은 자가면역질환 및 염증성 질환의 유병률 증가, 생물학적 치료의 발전, 조기 진단의 중요성에 대한 인식 증가 등 여러 가지 요인에 기인합니다. TNF 억제제와 IL-17 억제제가 1차 치료제로 채택되면서 환자의 예후가 크게 개선되어 시장 확대에 박차를 가하고 있습니다. 또한, JAK 억제제 및 기타 신규 생물학적 제제를 포함한 차세대 치료제의 개발로 AS 관리의 미충족 수요를 충족시키고 있습니다. 자가주사 등 보다 편리하고 효과적인 치료법을 원하는 소비자 수요는 약물 전달 시스템의 기술 혁신을 촉진하고 있습니다. 특히 신흥 시장에서는 의료 접근성 및 의료비 부담을 개선하기 위한 지역 정부의 이니셔티브이 첨단 치료법의 채택을 더욱 촉진하고 있습니다. 또한, 원격 의료 및 원격 모니터링을 포함한 디지털 건강 도구의 통합은 더 나은 질병 관리와 치료 순응도를 촉진하고 있습니다. 이러한 요인들이 종합적으로 강직성 척추염 시장의 견고한 성장 궤적과 이 만성 질환의 세계 부담을 해결하는 데 있어 중요한 역할을 강조하고 있습니다.

부문

약제 클래스(TNF 억제제 클래스, 비스테로이드성 항염증제클래스, 기타 약제 클래스별), 유통 채널(병원 약국, 소매 약국, 기타 유통 채널)

조사 대상 기업 예

  • AbbVie, Inc.
  • Akeso Biopharma Co., Ltd.
  • Amgen, Inc.
  • Coherus Biosciences, Inc.
  • Eli Lilly and Company
  • Johnson & Johnson Innovative Medicine UK
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Trinity Biotech PLC
  • UCB SA
  • ViennaLab Diagnostics GmbH
  • Zydus Lifesciences Limited

AI 통합

우리는 검증된 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.13

Global Ankylosing Spondylitis Market to Reach US$8.1 Billion by 2030

The global market for Ankylosing Spondylitis estimated at US$6.0 Billion in the year 2024, is expected to reach US$8.1 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. TNF Inhibitors Drug Class, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$4.4 Billion by the end of the analysis period. Growth in the NSAIDs Drug Class segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 8.4% CAGR

The Ankylosing Spondylitis market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Ankylosing Spondylitis Market - Key Trends & Drivers Summarized

Why Is Ankylosing Spondylitis Becoming a Critical Global Health Concern?

Ankylosing spondylitis (AS), a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, is gaining recognition as a significant global health concern due to its debilitating nature and long-term impact on quality of life. AS primarily affects young adults, with symptoms often beginning in the late teens or early twenties. The progressive nature of the disease, characterized by chronic pain, stiffness, and potential spinal fusion, underscores the need for effective therapeutic interventions to manage symptoms and prevent complications. Moreover, the rising prevalence of ankylosing spondylitis worldwide has led to increased demand for targeted treatment options. While the exact cause of AS remains unclear, genetic predisposition, particularly the presence of the HLA-B27 gene, has been identified as a major risk factor. This has prompted advancements in precision medicine approaches, enabling tailored treatment strategies for individuals with AS. Additionally, the societal and economic burden of the disease, including loss of productivity and healthcare costs, has heightened the focus on improving access to effective therapies.

What Advancements Are Driving the Development of AS Treatments?

The treatment landscape for ankylosing spondylitis has evolved significantly, driven by advancements in biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs). Tumor necrosis factor (TNF) inhibitors, such as adalimumab and infliximab, have been pivotal in transforming the management of AS by reducing inflammation, slowing disease progression, and improving patient outcomes. The introduction of interleukin (IL)-17 inhibitors, including secukinumab and ixekizumab, has further expanded treatment options, particularly for patients who do not respond to TNF inhibitors. Innovations in drug delivery systems, such as self-administered subcutaneous injections and extended-release formulations, have improved patient compliance and convenience. Furthermore, advancements in diagnostic tools, including magnetic resonance imaging (MRI) and genetic testing, are facilitating earlier detection of AS, enabling timely intervention and better disease management. Ongoing research into novel therapeutic targets, such as Janus kinase (JAK) inhibitors, holds promise for expanding the range of effective treatment options in the near future.

How Are Regional Dynamics Influencing Market Growth?

The ankylosing spondylitis market exhibits significant regional variations, influenced by differences in disease prevalence, healthcare infrastructure, and access to advanced treatments. North America dominates the market, driven by a high prevalence of autoimmune diseases, robust healthcare systems, and substantial investments in research and development. The region also benefits from favorable reimbursement policies and widespread availability of advanced biologic therapies. Europe follows closely, with a strong focus on early diagnosis and the integration of innovative treatments into standard care protocols. Countries such as Germany, the UK, and France have well-established rheumatology networks, ensuring better disease management and patient outcomes. In the Asia-Pacific region, the market is expanding rapidly due to increasing disease awareness, improving healthcare access, and rising disposable incomes. Emerging economies such as China and India are witnessing growing adoption of biologic therapies, supported by government initiatives to enhance healthcare infrastructure. Meanwhile, Latin America and the Middle East are gradually embracing advanced treatments, although challenges related to affordability and awareness persist.

What Is Driving Growth in the Ankylosing Spondylitis Market?

The growth in the ankylosing spondylitis market is driven by several factors, including the rising prevalence of autoimmune and inflammatory diseases, advancements in biologic therapies, and increasing awareness of the importance of early diagnosis. The growing adoption of TNF inhibitors and IL-17 inhibitors as first-line treatments has significantly improved patient outcomes, fueling market expansion. Additionally, the development of next-generation therapies, including JAK inhibitors and other novel biologics, is addressing unmet needs in AS management. Consumer demand for more convenient and effective treatment options, such as self-administered injections, has spurred innovation in drug delivery systems. Regional government initiatives to improve healthcare access and affordability, particularly in emerging markets, are further driving the adoption of advanced therapies. Moreover, the integration of digital health tools, including telemedicine and remote monitoring, is facilitating better disease management and treatment adherence. These factors collectively highlight the robust growth trajectory of the ankylosing spondylitis market and its critical role in addressing the global burden of this chronic condition.

SCOPE OF STUDY:

The report analyzes the Ankylosing Spondylitis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (TNF Inhibitors Drug Class, NSAIDs Drug Class, Other Drug Classes); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie, Inc.
  • Akeso Biopharma Co., Ltd.
  • Amgen, Inc.
  • Coherus Biosciences, Inc.
  • Eli Lilly and Company
  • Johnson & Johnson Innovative Medicine UK
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Trinity Biotech PLC
  • UCB SA
  • ViennaLab Diagnostics GmbH
  • Zydus Lifesciences Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Ankylosing Spondylitis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Ankylosing Spondylitis Propels Demand for Early Diagnosis and Treatment Solutions
    • Growing Awareness About Autoimmune Disorders Expands Addressable Market Opportunity for AS Therapeutics
    • Advancements in Biologics and Targeted Therapies Drive Innovation in Ankylosing Spondylitis Treatment
    • Rising Adoption of Biosimilars Spurs Market Growth for Cost-Effective Ankylosing Spondylitis Treatment Options
    • Increased Focus on Personalized Medicine Generates Demand for Tailored AS Treatment Approaches
    • Integration of Digital Health & Telemedicine Improves Accessibility and Compliance in AS Management
    • Growing Role of Lifestyle and Physiotherapy Interventions Sustains Market Growth for Holistic AS Care
    • Expanding Application of Artificial Intelligence in Disease Diagnosis and Drug Discovery Accelerates AS Market Developments
    • Regulatory Support for Fast-Track Approvals Expedites Market Entry of Innovative AS Therapies
    • Patient Advocacy and Support Groups Strengthen Market Dynamics Through Awareness and Education Initiatives
    • Challenges Related to High Cost of Biologic Therapies Impact Market Penetration in Low-Income Regions
    • Rising Healthcare Expenditure and Insurance Coverage Expansion Drive Adoption of AS Treatment Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Ankylosing Spondylitis Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Ankylosing Spondylitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Ankylosing Spondylitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for TNF Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for TNF Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for TNF Inhibitors Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for NSAIDs Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for NSAIDs Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for NSAIDs Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Ankylosing Spondylitis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Ankylosing Spondylitis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Ankylosing Spondylitis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Ankylosing Spondylitis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Ankylosing Spondylitis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Ankylosing Spondylitis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Ankylosing Spondylitis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Ankylosing Spondylitis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Ankylosing Spondylitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Ankylosing Spondylitis by Drug Class - TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Ankylosing Spondylitis by Drug Class - Percentage Breakdown of Value Sales for TNF Inhibitors Drug Class, NSAIDs Drug Class and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Ankylosing Spondylitis by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Ankylosing Spondylitis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제